The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus today after the company released encouraging Part 1 results from its global Phase 3 ProstACT study of TLX591-Tx, its novel prostate cancer therapy. Key results showed the therapy demonstrated an acceptable and manageable safety profile, with no new safety signals and sustained tumour uptake across patients.
Image source: Getty Images
What did Telix Pharmaceuticals report?
- ProstACT Global Phase 3 (Part 1) met key objectives for safety, pharmacokinetics, and dosimetry.
- No new safety signals or adverse drug–drug interactions were observed in the study.
- Low radiation exposure to salivary glands and kidneys, supporting tolerability.
- Most prevalent side effects were fatigue (53%), nausea (28%), and dry mouth (25%), with nearly all cases being mild or moderate.
- Platelet counts recovered to safe levels on average 15 days after treatment nadir.
What else do investors need to know?
The ProstACT Global study enrolled 36 patients with advanced prostate cancer, all of whom received two doses of TLX591-Tx in combination with standard therapies. Thirty-two patients remain alive, and 26 are continuing in the trial.
Telix emphasised that TLX591-Tx offers a patient-friendly, two-dose regimen, aiding treatment compliance and integration with existing standards of care. The therapy's pharmacokinetic profile showed sustained tumour retention and consistent results across different patient cohorts.
What's next for Telix Pharmaceuticals?
With Part 1 complete, Telix is seeking regulatory clearance to begin Part 2 of the Phase 3 trial in the US. Enrolment is already under way in Australia, New Zealand, and Canada, with further approvals obtained in Asia and Europe.
The company plans to continue expanding the study globally, with the ultimate goal of demonstrating long-term clinical benefit and securing approval for TLX591-Tx as a new treatment option for patients with metastatic prostate cancer.
Telix Pharmaceuticals share price snapshot
Over the past 12 months, Telix Pharmaceuticals shares have declined 63%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 8% over the same period.
